摘要
慢性阻塞性肺疾病(慢阻肺)全球创议(global initiative for chronic obstructive lung disease,GOLD)2020年修订版于2019年11月5日发布,其最重要的改变是增加了起始吸入性糖皮质激素治疗需要考虑的因素,调整了慢阻肺管理循环图表,改进了非药物治疗的随访,并明确了慢阻肺急性加重的鉴别诊断。本文对新增内容进行简介和解读。
Global initiative for chronic obstructive lung disease(GOLD)2020 report was released on Nov 5,2019.The GOLD 2020 report is a minor revision of the GOLD 2017 report.This article mainly focus on factors to consider when initiating ICS treatment,management of COPD,follow-up of non-pharmacological treatment,and differential diagnosis of COPD exacerbation in GOLD 2020 report.
作者
陈亚红
CHEN Ya-hong(Department of Respiratory and Critical Care Medicine,Peking University Third Hospital,Beijing 100191,China)
出处
《中国医学前沿杂志（电子版）》
2019年第12期32-50,共19页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
国家重点研发计划“重大慢性非传染性疾病防控研究”专项课题(2016YFC1304301)
精准医学研究专项(2016YFC0903601,2016YFC0901102)
关键词
慢性阻塞性肺疾病
吸入性糖皮质激素
急性加重
生物标志物
个体化治疗
Chronic obstructive pulmonary disease
Inhaled corticosteroid
Acute exacerbation
Biomarkers
Individualized treatment
